Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha

Mol Cell Biol. 2003 Sep;23(17):6200-9. doi: 10.1128/MCB.23.17.6200-6209.2003.

Abstract

Previous studies have implicated acetylases and deacetylases in regulating the transcriptional activity of NF-kappa B. Here, we show that inhibitors of deacetylases such as trichostatin A (TSA) and sodium butyrate (NaBut) potentiated TNF-induced expression of several natural NF-kappa B-driven promoters. This transcriptional synergism observed between TNF and TSA (or NaBut) required intact kappa B sites in all promoters tested and was biologically relevant as demonstrated by RNase protection on two instances of endogenous NF-kappa B-regulated gene transcription. Importantly, TSA prolonged both TNF-induced DNA-binding activity and the presence of NF-kappa B in the nucleus. We showed that the p65 subunit of NF-kappa B was acetylated in vivo. However, this acetylation was weak, suggesting that other mechanisms could be implicated in the potentiated binding and transactivation activities of NF-kappa B after TNF plus TSA versus TNF treatment. Western blot and immunofluorescence confocal microscopy experiments revealed a delay in the cytoplasmic reappearance of the I kappa B alpha inhibitor that correlated temporally with the prolonged intranuclear binding and presence of NF-kappa B. This delay was due neither to a defect in I kappa B alpha mRNA production nor to a nuclear retention of I kappa B alpha but was rather due to a persistent proteasome-mediated degradation of I kappa B alpha. A prolongation of I kappa B kinase activity could explain, at least partially, the delayed I kappa B alpha cytoplasmic reappearance observed in presence of TNF plus TSA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Butyric Acid / pharmacology
  • Cysteine Endopeptidases
  • Cytoplasm / metabolism*
  • Enzyme Inhibitors / pharmacology*
  • HeLa Cells
  • Histone Deacetylase Inhibitors*
  • Histone Deacetylases / metabolism
  • Humans
  • Hydroxamic Acids / pharmacology
  • I-kappa B Kinase
  • I-kappa B Proteins / drug effects
  • I-kappa B Proteins / genetics
  • I-kappa B Proteins / metabolism*
  • Leupeptins / pharmacology
  • Mitogen-Activated Protein Kinases / drug effects
  • Mitogen-Activated Protein Kinases / metabolism
  • Multienzyme Complexes / antagonists & inhibitors
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / drug effects
  • NF-kappa B / genetics
  • NF-kappa B / metabolism*
  • Proteasome Endopeptidase Complex
  • Protein Serine-Threonine Kinases / drug effects
  • Protein Serine-Threonine Kinases / metabolism
  • Protein Transport / drug effects
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • I-kappa B Proteins
  • Leupeptins
  • Multienzyme Complexes
  • NF-kappa B
  • NFKBIA protein, human
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Butyric Acid
  • NF-KappaB Inhibitor alpha
  • trichostatin A
  • Protein Serine-Threonine Kinases
  • CHUK protein, human
  • I-kappa B Kinase
  • IKBKB protein, human
  • IKBKE protein, human
  • Mitogen-Activated Protein Kinases
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • Histone Deacetylases
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde